NCT00003457 · OUTCOME

Percentage of Participants Who Survived

Antineoplaston Therapy in Treating Patients With Brain Tumors · Source last updated 2017-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: Not reported
Time frame: 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

What was measured

6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival

Analysis population: All study subjects receiving any Antineoplaston therapy

Groups in this outcome

Antineoplaston Therapy

Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Antineoplaston Therapy	40

Reported measurements

6 months overall survival

Values in Percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Antineoplaston Therapy	70.0	Not reported	Not reported	Not reported	Not reported

12 months overall survival

Values in Percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Antineoplaston Therapy	50.0	Not reported	Not reported	Not reported	Not reported

24 months overall survival

Values in Percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Antineoplaston Therapy	40.0	Not reported	Not reported	Not reported	Not reported

36 months overall survival

Values in Percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Antineoplaston Therapy	35.0	Not reported	Not reported	Not reported	Not reported

48 months overall survival

Values in Percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Antineoplaston Therapy	30.0	Not reported	Not reported	Not reported	Not reported

60 months overall survival

Values in Percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Antineoplaston Therapy	22.5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
70.0
title
6 months overall survival
categories
measurements
group Id
OG000
value
50.0
title
12 months overall survival
categories
measurements
group Id
OG000
value
40.0
title
24 months overall survival
categories
measurements
group Id
OG000
value
35.0
title
36 months overall survival
categories
measurements
group Id
OG000
value
30.0
title
48 months overall survival
categories
measurements
group Id
OG000
value
22.5
title
60 months overall survival

denoms

counts
group Id
OG000
value
40
units
Participants

description

6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival

groups

description
Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
id
OG000
title
Antineoplaston Therapy

param Type

NUMBER

population Description

All study subjects receiving any Antineoplaston therapy

reporting Status

POSTED

time Frame

6 months, 12 months, 24 months, 36 months, 48 months, 60 months

title

Percentage of Participants Who Survived

type

SECONDARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice